Literature DB >> 9468119

Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function.

J J Baskett1, J F Cockrem, T A Antunovich.   

Abstract

In order to validate measurement of urinary sulphatoxymelatonin as an accurate method of estimating plasma melatonin secretion in older people, we compared 24 h plasma melatonin secretion and sulphatoxymelatonin excretion with renal function in 20 subjects 62-89 years of age. There was a good correlation between plasma and urinary sulphatoxymelatonin over the same 24 h period (R2 = 0.797) and no relationship between creatinine clearance and sulphatoxymelatonin excretion (R2 = 0.075). The results suggest that sulphatoxymelatonin excretion estimation is a good surrogate measurement of plasma melatonin secretion in older people, at least across the range of creatinine clearance for the subjects in the study, 0.41-1.81 ml/sec.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468119     DOI: 10.1111/j.1600-079x.1998.tb00366.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  24 in total

1.  Sleep disorders and inflammatory disease activity: chicken or the egg?

Authors:  Parth J Parekh; Edward C Oldfield Iv; Vaishnavi Challapallisri; J Catsby Ware; David A Johnson
Journal:  Am J Gastroenterol       Date:  2014-08-26       Impact factor: 10.864

2.  Secretion of melatonin and 6-sulfatoxymelatonin urinary excretion in functional dyspepsia.

Authors:  Cezary Chojnacki; Tomasz Poplawski; Grażyna Klupinska; Janusz Blasiak; Jan Chojnacki; Russel J Reiter
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

Review 3.  Light at night as an environmental endocrine disruptor.

Authors:  Kathryn L G Russart; Randy J Nelson
Journal:  Physiol Behav       Date:  2017-09-07

Review 4.  Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Authors:  N Zisapel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Melatonin secretion and the incidence of type 2 diabetes.

Authors:  Ciaran J McMullan; Eva S Schernhammer; Eric B Rimm; Frank B Hu; John P Forman
Journal:  JAMA       Date:  2013-04-03       Impact factor: 56.272

6.  Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.

Authors:  Eva S Schernhammer; Franco Berrino; Vittorio Krogh; Giorgio Secreto; Andrea Micheli; Elisabetta Venturelli; Sara Grioni; Christopher T Sempos; Adalberto Cavalleri; Holger J Schünemann; Sabrina Strano; Paola Muti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

7.  Association of urinary melatonin levels and aging-related outcomes in older men.

Authors:  Elizabeth E Devore; Stephanie L Harrison; Katie L Stone; Kathleen F Holton; Elizabeth Barrett-Connor; Sonia Ancoli-Israel; Kristine Yaffe; Kristine Ensrud; Peggy M Cawthon; Susan Redline; Eric Orwoll; Eva S Schernhammer
Journal:  Sleep Med       Date:  2016-08-04       Impact factor: 3.492

8.  Is melatonin synthesis a new biomarker for the pathogenesis and treatment of phenylketonuria?

Authors:  Stephen Cederbaum; Harvey L Levy
Journal:  J Pediatr       Date:  2013-01-11       Impact factor: 4.406

9.  Impaired endogenous nighttime melatonin secretion relates to intrarenal renin-angiotensin system activation and renal damage in patients with chronic kidney disease.

Authors:  Sayaka Ishigaki; Naro Ohashi; Shinsuke Isobe; Naoko Tsuji; Takamasa Iwakura; Masafumi Ono; Yukitoshi Sakao; Takayuki Tsuji; Akihiko Kato; Hiroaki Miyajima; Hideo Yasuda
Journal:  Clin Exp Nephrol       Date:  2016-01-07       Impact factor: 2.801

10.  Urinary melatonin and risk of incident hypertension among young women.

Authors:  John P Forman; Gary C Curhan; Eva S Schernhammer
Journal:  J Hypertens       Date:  2010-03       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.